WASHINGTON (AP) — President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and conservative lawmakers despite having serious safety risks.
Ibogaine and other psychedelics remain banned under the federal government’s most restrictive category for illegal, high-risk drugs. But the administration is taking steps to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said as he signed an executive order on the drugs. The Republican president said his directive will help “dramatically accelerate” access to potential treatments. “If these turn out to be as good as people are saying, it’s going to have a tremendous impact,” he said.
Veteran organizations and psychedelic advocates have long contended that ibogaine, which is made from a shrub native to West Africa, has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction.
Trump’s announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support.
Joining Trump in the Oval Office were his top health officials, conservative podcaster Joe Rogan and Marcus Luttrell, the former Navy SEAL whose memoir about a deadly mission in Afghanistan was the basis of the film “Lone Survivor.” Rogan said he texted Trump information on ibogaine and the president responded: “Sounds great. Do you want FDA approval? Let’s do it.”
“You’re going to save a lot of lives through it,” Luttrell told Trump during the ceremony. “It absolutely changed my life for the better.”
Trump’s announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support.
Joining Trump in the Oval Office were his top health officials, conservative podcaster Joe Rogan and Marcus Luttrell, the former Navy SEAL whose memoir about a deadly mission in Afghanistan was the basis of the film “Lone Survivor.” Rogan said he texted Trump information on ibogaine and the president responded: “Sounds great. Do you want FDA approval? Let’s do it.”
“You’re going to save a lot of lives through it,” Luttrell told Trump during the ceremony. “It absolutely changed my life for the better.”
“It’s been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity,” said Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research. “If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others.”
No psychedelic has been approved in the United States, but a number of them are being studied in large trials for various mental health conditions, including psilocybin, MDMA and LSD. All those drugs remain illegal, classified as Schedule I substances alongside drugs such as heroin. Two states — Oregon and Colorado — have legalized psychedelic therapy with psilocybin.
Ibogaine was first used by members of the Bwiti religion in African nations like Gabon during their religious ceremonies.
In recent years, U.S. veterans have reported benefiting from the drug after traveling to clinics in Mexico that administer it.
Backing from veterans groups and former Texas Gov. Rick Perry led to a law last year providing $50 million for ibogaine research in that state. Perry, who co-founded a group called Americans for Ibogaine, recently appeared on Rogan’s podcast, making the case for reducing federal limits on the drug. It was his second time talking about ibogaine on the popular podcast in the past two years.
Trump’s order calls on the Department of Health and Human Services to direct at least $50 million to states that have enacted or are developing programs to advance psychedelic drugs for serious mental illness. It’s described as a federal-state partnership to provide funding, technical assistance and data sharing.
About the Author
Dang, there you all go again. This lady deserves more than a double rude welcome. She deserves an apology. If…
I bet she voted for Kamal-Toe, Sleepy-Joe, Crooked-Hillary and Bath-house Barry (if she was old enough).
I'll be running in the next town council election.
You're right Butters. Many people are Profiting from the Rape of the Bay including politicians and officials. Meanwhile Omega is…
CBF has to keep the movement going. They don't care about science unless it serves their narrative.. Which isn't unusual…